Please assess the completion status of the following clinical trial:

Trial Title: Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for all study participants:~* Right-Handedness~Exclusion Criteria for all study participants:~* Any clinically significant history of cardiac problems~* Any current Axis I psychiatric diagnosis as verified by the Structured Clinical Interview for DSM-IV (other than participants with ADHD or history of alcohol dependence)~* A previous adequate trial with methylphenidate (Ritalin) or naltrexone (ReVia)~* Currently taking any psychoactive medications~* Any clinically significant medical condition~* Any clinically significant neurological problem (seizures, tics, serious head injury)~* Contraindications to MRI (metal objects in body or claustrophobia)~* Currently pregnant or lactating~* Alcohol or substance abuse (current or in the past 2 years)~* Left-handedness or ambidextrous~* Liver or kidney disease~Inclusion Criteria for the participants with ADHD:~* Currently un-medicated adults with ADHD~* Has met full DSM-IV-R criteria (at least six of nine symptoms)for inattentive or hyperactive/impulsive subtypes (or both) by age 7 as well within the past month~* Has described a chronic course of ADHD symptomatology from childhood to adulthood~* Has endorsed a moderate or severe level of impairment attributed to the ADHD symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: EXPERIMENTAL): Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
- Adult Attention-Deficit/Hyperactivity Disorder (Type: EXPERIMENTAL): ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.

Based on this trial design, predict the completion outcome and termination type (if applicable).